Nel (Sell, TP: NOK3.50) - Facing one-off tailwind in Q1
We forecast Q1 EBITDA of NOK4m, well above consensus of NOK-59m, as we believe consensus does not fully capture one-off gains related to compensation for the cancellation of the Nikola agreement. We still see a risk to collections of the missing payments from its largest client last year (representing 26% of revenue), and any comment on this project should be key. Still-limited order intake raises concerns about future growth, as our estimates and consensus assume large-scale orders materialising. Applying key peer Thyssenkrupp Nucera’s EV/sales suggests a fair value of cNOK3–3.5/share for Nel, implying c35% downside potential. We reiterate our SELL and NOK3.5 target price.NEL ASA develops diagnostic tests for early detection of diseases. Co.'s patented method is based on identifying disease-specific gene expression signatures from sample materials, such as blood. Co.'s products in development phase include MCItect, for patients with Mild Cognitive Impairment (MCI) aimed to detect Alzheimer disease within two years prior to onset of dementia, and ADtect, for the detection of mild to moderate Alzheimer disease, as well as one project in discovery phase, namely AMYtect, for brain amyloid detection.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.